-
-
safety,quality,efficacy -
safety,quality,efficacy -
safety,quality,efficacy
provide users with high-quality blood products
-
2024/06/25shanghai raas was awarded the 15th china listed company investor relations tianma award.view details
-
-462.jpg)
2024/05/29shanghai raas was ranked fifth in the 2024 "sfeo shanghai productive service industry brand value list"view details
-
-
2024/03/20shanghai raas and boehringer-ingelheim reached a major cooperation to jointly develop innovative drugs for hemophilia
-
2023/12/18some products of shanghai raas cancel the limited payment scope of medical insurance
-
2023/03/01shanghai raas was re-awarded the title of "leading enterprise of oriental beauty valley".
-
about raas
being vital for life saving, blood products are important national strategic reserve materials. founded in 1988 and situated at no. 2009 wangyuan road, fengxian district, shanghai with a registered capital of rmb 6,740,787,907.00, shanghai raas was listed on the shenzhen stock exchange in june 2008 as a leading domestic blood products company that integrates source plasma collection, blood products research and development, production and sales.
-
36 years extensive industry experience
-
5 units production bases
-
44 centers plasma donation center
0.20 ( 3.13%)
raas plasma donation center
as of dec 2023, shanghai raas and its subsidiaries had 44 plasma donation centers (including newly approved ) in china including those under construction, of which 18 are shanghai raas , 19 are tonrol biopharmaceutical, 2 are zhengzhou raas,3 are zhejiang haikang biopharmaceutical and 2 are guangxi raas, covering 11 provinces (autonomous regions) in guangxi, hunan, hainan, shaanxi, anhui, guangdong, inner mongolia, zhejiang, hubei, jiangxi and shandong.
-
18 centers shanghai raas (including one subcenter)
-
19 centers tonrol biopharmaceutical
-
2 centers zhengzhou raas
-
3 centers zhejiang haikang biopharmaceutical
-
2 centers guangxi raas
